GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » PS Ratio

Exelixis (Exelixis) PS Ratio

: 3.95 (As of Today)
View and export this data going back to 2000. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Exelixis's share price is $22.52. Exelixis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $5.70. Hence, Exelixis's PS Ratio for today is 3.95.

The historical rank and industry rank for Exelixis's PS Ratio or its related term are showing as below:

EXEL' s PS Ratio Range Over the Past 10 Years
Min: 3.05   Med: 8.58   Max: 47.27
Current: 4.01

During the past 13 years, Exelixis's highest PS Ratio was 47.27. The lowest was 3.05. And the median was 8.58.

EXEL's PS Ratio is ranked better than
71.39% of 996 companies
in the Biotechnology industry
Industry Median: 8.985 vs EXEL: 4.01

Exelixis's Revenue per Sharefor the three months ended in Dec. 2023 was $1.53. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $5.70.

During the past 12 months, the average Revenue per Share Growth Rate of Exelixis was 14.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 22.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 16.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 51.10% per year.

During the past 13 years, Exelixis's highest 3-Year average Revenue per Share Growth Rate was 148.50% per year. The lowest was -61.30% per year. And the median was 13.10% per year.

Back to Basics: PS Ratio


Exelixis PS Ratio Historical Data

The historical data trend for Exelixis's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.74 6.46 4.11 3.23 4.21

Exelixis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 3.79 3.63 3.99 4.21

Competitive Comparison

For the Biotechnology subindustry, Exelixis's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Exelixis's PS Ratio distribution charts can be found below:

* The bar in red indicates where Exelixis's PS Ratio falls into.



Exelixis PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Exelixis's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=22.52/5.699
=3.95

Exelixis's Share Price of today is $22.52.
Exelixis's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.70.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Exelixis  (NAS:EXEL) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Exelixis PS Ratio Related Terms

Thank you for viewing the detailed overview of Exelixis's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (Exelixis) Business Description

Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
Patrick J. Haley officer: Sr. Vice President, Commercial 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel officer: EVP and General Counsel 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson director 590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab officer: CSO/EVP Disc & Trans Research EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson officer: EVP Prod Dev & Med Aff & CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner officer: EVP and CFO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp director, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski director SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber director 3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum director C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb officer: EVP, Discovery Research & CSO PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste director 515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083

Exelixis (Exelixis) Headlines

From GuruFocus

Exelixis Advances Board Refreshment Plan

By Business Wire Business Wire 04-13-2023